Low risk of solid tumors in persons with Down syndrome

Genetics in Medicine

Volumn 18, Issue 11, 2016, Pages 1151-1157

  Hasle, Henrik ^a   Friedman, Jan M ^b   Olsen, Jørgen H ^c   Rasmussen, Sonja A ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

cancer; Down syndrome; tumor suppressor genes

Indexed keywords

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; DOWN SYNDROME; EMBRYONAL CARCINOMA; FEMALE; HISTOLOGY; HUMAN; INFANT; KARYOTYPE; LEUKEMIA; LOW RISK POPULATION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOSAICISM; ROBERTSONIAN CHROMOSOME TRANSLOCATION; SEMINOMA; SOLID TUMOR; STANDARDIZED INCIDENCE RATIO; TESTIS CANCER; TRISOMY 21; UTERINE CERVIX CANCER; AGED; CHILD; COMPLICATION; GENETICS; MIDDLE AGED; PRESCHOOL CHILD; REGISTER; RISK FACTOR; TESTICULAR NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TESTICULAR NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84994141286     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.23     Document Type: Article

References (39)

1. de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A 2015;167A:756-767.
2. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281-1289.
3. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001;2:429-436.
4. Zhu JL, Hasle H, Correa A, et al. Survival among people with Down syndrome: a nationwide population-based study in Denmark. Genet Med 2013;15:64-69.
5. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-169.
6. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002;359:1019-1025.
7. Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer 2006;118:1769-1772.
8. Sullivan SG, Hussain R, Glasson EJ, Bittles AH. The profile and incidence of cancer in Down syndrome. J Intellect Disabil Res 2007;51(Pt 3):228-231.
9. Hasle H, Olsen JH, Nielsen J, Hansen J, Friedrich U, Tommerup N. Occurrence of cancer in women with Turner syndrome. Br J Cancer 1996;73:1156-1159.
10. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997;44:535-539.
11. Satgé D, Sasco AJ, Day S, Culine S. A lower risk of dying from urological cancer in Down syndrome: clue for cancer protecting genes on chromosome 21. Urol Int 2009;82:296-300.
12. Satgé D, Stiller CA, Rutkowski S, et al. A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. J Neurooncol 2013;112:107-114.
13. Maloney KW, Taub JW, Ravindranath Y, Roberts I, Vyas P. Down syndrome preleukemia and leukemia. Pediatr Clin North Am 2015;62:121-137.
14. Lane AA, Chapuy B, Lin CY, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet 2014;46:618-623.
15. Beacher F, Daly E, Simmons A, et al. Brain anatomy and ageing in non-demented adults with Down's syndrome: an in vivo MRI study. Psychol Med 2010;40: 611-619.
16. Niẑeti? D, Groet J. Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat Rev Cancer 2012;12:721-732.
17. Brugge KL, Grove GL, Clopton P, Grove MJ, Piacquadio DJ. Evidence for accelerated skin wrinkling among developmentally delayed individuals with Down's syndrome. Mech Ageing Dev 1993;70:213-225.
18. Rueda N, Flórez J, Martínez-Cué C. Apoptosis in Down's syndrome: lessons from studies of human and mouse models. Apoptosis 2013;18:121-134.
19. Boker LK, Merrick J. Cancer incidence in persons with Down syndrome in Israel. Downs Syndr Res Pract 2002;8:31-36.
20. Hermon C, Alberman E, Beral V, Swerdlow AJ. Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. Ann Hum Genet 2001;65(Pt 2):167-176.
21. Hill DA, Gridley G, Cnattingius S, et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med 2003;163:705-711.
22. Vachon L, Fareau GE, Wilson MG, Chan LS. Testicular microlithiasis in patients with Down syndrome. J Pediatr 2006;149:233-236.
23. Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 2007;356: 1835-1841.
24. Mercer ES, Broecker B, Smith EA, Kirsch AJ, Scherz HC, A Massad C. Urological manifestations of Down syndrome. J Urol 2004;171:1250-1253.
25. Miki M, Ohtake N, Hasumi M, Ohi M, Moriyama S. Seminoma associated with bilateral cryptorchidism in Down's syndrome: a case report. Int J Urol 1999;6:377-380.
26. Ottesen AM, Kirchhoff M, Rajpert De-Meyts E, et al. Detection of chromosomal aberrations in seminomatous germ cell tumours using comparative genomic hybridization. Genes Chromosomes Cancer 1997;20:412-418.
27. Zhu JL, Obel C, Hasle H, Rasmussen SA, Li J, Olsen J. Social conditions for people with Down syndrome: a register-based cohort study in Denmark. Am J Med Genet A 2014;164A:36-41.
28. Bell AJ, Bhate MS. Prevalence of overweight and obesity in Down's syndrome and other mentally handicapped adults living in the community. J Intellect Disabil Res 1992;36(Pt 4):359-364.
29. Hsieh K, Rimmer JH, Heller T. Obesity and associated factors in adults with intellectual disability. J Intellect Disabil Res 2014;58:851-863.
30. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Bodymass index and risk of 22 specific cancers: a population-based cohort study of 524 million UK adults. Lancet 2014;384:755-765.
31. Opdahl S, Alsaker MD, Janszky I, Romundstad PR, Vatten LJ. Joint effects of nulliparity and other breast cancer risk factors. Br J Cancer 2011;105:731-736.
32. Schupf N, Zigman W, Kapell D, Lee JH, Kline J, Levin B. Early menopause in women with Down's syndrome. J Intellect Disabil Res 1997;41(Pt 3): 264-267.
33. Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 2008;451:73-75.
34. Birger Y, Izraeli S. DYRK1A in Down syndrome: an oncogene or tumor suppressor? J Clin Invest 2012;122:807-810.
35. Greene AK, Kim S, Rogers GF, Fishman SJ, Olsen BR, Mulliken JB. Risk of vascular anomalies with Down syndrome. Pediatrics 2008;121:e135-e140.
36. Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-814.
37. Baek KH, Zaslavsky A, Lynch RC, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009;459: 1126-1130.
38. Shin J, Lee JC, Baek KH. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis. Cancer Lett 2014;342:70-81.
39. Sullivan SG, Glasson EJ, Hussain R, et al. Breast cancer and the uptake of mammography screening services by women with intellectual disabilities. Prev Med 2003;37:507-512.